Early on-treatment viral load and baseline METAVIR score: improved prediction of sustained virological response in HCV genotype 1 patients

Darrell Crawford, Gregory J Dore, William Sievert, Wendy Cheng, Martin D Weltman, Geoffrey McCaughan, William Rawlinson, Phillipa Marks, Motoko Yoshihara, Bishoy Rizkalla, Stuart K Roberts

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)

Abstract

BACKGROUND: On-treatment HCV viral load during early therapy with pegylated interferon (PEG-IFN) and ribavirin is highly predictive of sustained virological response (SVR). We sought to provide further refinement of this prediction through an extensive evaluation of the effect of HCV viral loads at weeks 4, 8 and 12 on SVR, including analysis by liver disease stage grouping. METHODS: A total of 309 patients with genotype 1 chronic HCV and recent liver biopsy enrolled in the CHARIOT study received 180 mug of PEG-IFN-alpha2a weekly with 1,000/1,200 mg of ribavirin daily. The probability of an SVR was estimated using baseline METAVIR fibrosis stage and HCV viral loads at weeks 4, 8 and 12. RESULTS: HCV RNA was undetectable in 27.5 , 50.3 and 62.6 of patients at weeks 4, 8 and 12, respectively. SVR was 80.0 , 76.8 and 72.4 among patients with undetectable HCV RNA at weeks 4, 8 and 12, respectively. SVR decreased in a progressive fashion with increasing HCV viral loads at each early time point, but was similar for patients with HCV viral load 1,000 IU/ml, and all HCV viral load categories at weeks 8 and 12. CONCLUSIONS: A combination of baseline fibrosis stage and on-treatment HCV viral load at early time points provides improved estimates for treatment response in patients with chronic HCV genotype 1.
Original languageEnglish
Pages (from-to)849 - 854
Number of pages6
JournalAntiviral Therapy
Volume17
Issue number5
DOIs
Publication statusPublished - 2012

Cite this

Crawford, Darrell ; Dore, Gregory J ; Sievert, William ; Cheng, Wendy ; Weltman, Martin D ; McCaughan, Geoffrey ; Rawlinson, William ; Marks, Phillipa ; Yoshihara, Motoko ; Rizkalla, Bishoy ; Roberts, Stuart K. / Early on-treatment viral load and baseline METAVIR score: improved prediction of sustained virological response in HCV genotype 1 patients. In: Antiviral Therapy. 2012 ; Vol. 17, No. 5. pp. 849 - 854.
@article{afc73f41f5ed4971b608f28a40d0b86f,
title = "Early on-treatment viral load and baseline METAVIR score: improved prediction of sustained virological response in HCV genotype 1 patients",
abstract = "BACKGROUND: On-treatment HCV viral load during early therapy with pegylated interferon (PEG-IFN) and ribavirin is highly predictive of sustained virological response (SVR). We sought to provide further refinement of this prediction through an extensive evaluation of the effect of HCV viral loads at weeks 4, 8 and 12 on SVR, including analysis by liver disease stage grouping. METHODS: A total of 309 patients with genotype 1 chronic HCV and recent liver biopsy enrolled in the CHARIOT study received 180 mug of PEG-IFN-alpha2a weekly with 1,000/1,200 mg of ribavirin daily. The probability of an SVR was estimated using baseline METAVIR fibrosis stage and HCV viral loads at weeks 4, 8 and 12. RESULTS: HCV RNA was undetectable in 27.5 , 50.3 and 62.6 of patients at weeks 4, 8 and 12, respectively. SVR was 80.0 , 76.8 and 72.4 among patients with undetectable HCV RNA at weeks 4, 8 and 12, respectively. SVR decreased in a progressive fashion with increasing HCV viral loads at each early time point, but was similar for patients with HCV viral load 1,000 IU/ml, and all HCV viral load categories at weeks 8 and 12. CONCLUSIONS: A combination of baseline fibrosis stage and on-treatment HCV viral load at early time points provides improved estimates for treatment response in patients with chronic HCV genotype 1.",
author = "Darrell Crawford and Dore, {Gregory J} and William Sievert and Wendy Cheng and Weltman, {Martin D} and Geoffrey McCaughan and William Rawlinson and Phillipa Marks and Motoko Yoshihara and Bishoy Rizkalla and Roberts, {Stuart K}",
year = "2012",
doi = "10.3851/IMP2104",
language = "English",
volume = "17",
pages = "849 -- 854",
journal = "Antiviral Therapy",
issn = "1359-6535",
publisher = "International Medical Press",
number = "5",

}

Crawford, D, Dore, GJ, Sievert, W, Cheng, W, Weltman, MD, McCaughan, G, Rawlinson, W, Marks, P, Yoshihara, M, Rizkalla, B & Roberts, SK 2012, 'Early on-treatment viral load and baseline METAVIR score: improved prediction of sustained virological response in HCV genotype 1 patients', Antiviral Therapy, vol. 17, no. 5, pp. 849 - 854. https://doi.org/10.3851/IMP2104

Early on-treatment viral load and baseline METAVIR score: improved prediction of sustained virological response in HCV genotype 1 patients. / Crawford, Darrell; Dore, Gregory J; Sievert, William; Cheng, Wendy; Weltman, Martin D; McCaughan, Geoffrey; Rawlinson, William; Marks, Phillipa; Yoshihara, Motoko; Rizkalla, Bishoy; Roberts, Stuart K.

In: Antiviral Therapy, Vol. 17, No. 5, 2012, p. 849 - 854.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Early on-treatment viral load and baseline METAVIR score: improved prediction of sustained virological response in HCV genotype 1 patients

AU - Crawford, Darrell

AU - Dore, Gregory J

AU - Sievert, William

AU - Cheng, Wendy

AU - Weltman, Martin D

AU - McCaughan, Geoffrey

AU - Rawlinson, William

AU - Marks, Phillipa

AU - Yoshihara, Motoko

AU - Rizkalla, Bishoy

AU - Roberts, Stuart K

PY - 2012

Y1 - 2012

N2 - BACKGROUND: On-treatment HCV viral load during early therapy with pegylated interferon (PEG-IFN) and ribavirin is highly predictive of sustained virological response (SVR). We sought to provide further refinement of this prediction through an extensive evaluation of the effect of HCV viral loads at weeks 4, 8 and 12 on SVR, including analysis by liver disease stage grouping. METHODS: A total of 309 patients with genotype 1 chronic HCV and recent liver biopsy enrolled in the CHARIOT study received 180 mug of PEG-IFN-alpha2a weekly with 1,000/1,200 mg of ribavirin daily. The probability of an SVR was estimated using baseline METAVIR fibrosis stage and HCV viral loads at weeks 4, 8 and 12. RESULTS: HCV RNA was undetectable in 27.5 , 50.3 and 62.6 of patients at weeks 4, 8 and 12, respectively. SVR was 80.0 , 76.8 and 72.4 among patients with undetectable HCV RNA at weeks 4, 8 and 12, respectively. SVR decreased in a progressive fashion with increasing HCV viral loads at each early time point, but was similar for patients with HCV viral load 1,000 IU/ml, and all HCV viral load categories at weeks 8 and 12. CONCLUSIONS: A combination of baseline fibrosis stage and on-treatment HCV viral load at early time points provides improved estimates for treatment response in patients with chronic HCV genotype 1.

AB - BACKGROUND: On-treatment HCV viral load during early therapy with pegylated interferon (PEG-IFN) and ribavirin is highly predictive of sustained virological response (SVR). We sought to provide further refinement of this prediction through an extensive evaluation of the effect of HCV viral loads at weeks 4, 8 and 12 on SVR, including analysis by liver disease stage grouping. METHODS: A total of 309 patients with genotype 1 chronic HCV and recent liver biopsy enrolled in the CHARIOT study received 180 mug of PEG-IFN-alpha2a weekly with 1,000/1,200 mg of ribavirin daily. The probability of an SVR was estimated using baseline METAVIR fibrosis stage and HCV viral loads at weeks 4, 8 and 12. RESULTS: HCV RNA was undetectable in 27.5 , 50.3 and 62.6 of patients at weeks 4, 8 and 12, respectively. SVR was 80.0 , 76.8 and 72.4 among patients with undetectable HCV RNA at weeks 4, 8 and 12, respectively. SVR decreased in a progressive fashion with increasing HCV viral loads at each early time point, but was similar for patients with HCV viral load 1,000 IU/ml, and all HCV viral load categories at weeks 8 and 12. CONCLUSIONS: A combination of baseline fibrosis stage and on-treatment HCV viral load at early time points provides improved estimates for treatment response in patients with chronic HCV genotype 1.

UR - http://www.ncbi.nlm.nih.gov/pubmed/22513456

U2 - 10.3851/IMP2104

DO - 10.3851/IMP2104

M3 - Article

VL - 17

SP - 849

EP - 854

JO - Antiviral Therapy

JF - Antiviral Therapy

SN - 1359-6535

IS - 5

ER -